12/5
06:30 am
dsgn
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Low
Report
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
12/4
07:18 am
dsgn
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Medium
Report
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
12/3
08:05 am
dsgn
Design Therapeutics (NASDAQ:DSGN) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Medium
Report
Design Therapeutics (NASDAQ:DSGN) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
12/3
08:05 am
dsgn
Design Therapeutics (NASDAQ:DSGN) was given a new $14.00 price target on by analysts at Leerink Partners.
Medium
Report
Design Therapeutics (NASDAQ:DSGN) was given a new $14.00 price target on by analysts at Leerink Partners.
11/26
08:28 am
dsgn
Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/26
08:00 am
dsgn
Design Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Design Therapeutics to Participate in Upcoming Investor Conferences
11/20
11:53 am
dsgn
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says [Yahoo! Finance]
Medium
Report
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says [Yahoo! Finance]
11/20
08:01 am
dsgn
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating. They now have a $13.00 price target on the stock.
Medium
Report
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating. They now have a $13.00 price target on the stock.
11/8
01:12 am
dsgn
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at
Wall Stree
Low
Report
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at
Wall Stree
11/6
10:50 am
dsgn
Design Therapeutics (NASDAQ:DSGN) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $6.00. They now have a "sector perform" rating on the stock.
Medium
Report
Design Therapeutics (NASDAQ:DSGN) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $6.00. They now have a "sector perform" rating on the stock.
11/5
04:01 pm
dsgn
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Medium
Report
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
9/10
04:20 pm
dsgn
Design Therapeutics Appoints Justin Gover to Board of Directors [Yahoo! Finance]
Low
Report
Design Therapeutics Appoints Justin Gover to Board of Directors [Yahoo! Finance]
9/10
04:01 pm
dsgn
Design Therapeutics Appoints Justin Gover to Board of Directors
Low
Report
Design Therapeutics Appoints Justin Gover to Board of Directors